Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

v3.20.2
Significant Accounting Policies (Tables)
9 Months Ended
Jun. 30, 2020
Significant Accounting Policies  
Schedule of fair value hierarchy for its warrant liabilities measured at fair value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

Fair Value Measurements 

 

 

as of June 30, 2020

 

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

Total

Liabilities

 

 

  

 

 

  

 

 

  

 

 

  

Warrant liabilities

 

$

 —

 

 

 —

 

 

1,405,817

 

$

1,405,817

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements 

 

 

as of September 30, 2019

 

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

 Total  

Liabilities

 

 

  

 

 

  

 

 

  

 

 

 

Warrant liabilities

 

$

 —

 

 

 —

 

 

496,343

 

$

496,343

 

Schedule of assumptions were used in determining the fair value of the warrant liabilities

 

 

 

 

    

 

 

 

As of

 

 

June 30, 

 

 

2020

Remaining contractual term (years)

 

1.5 - 1.8

Common stock price volatility

 

87.9% - 89.8%

Risk-free interest rate

 

0.16%

Expected dividend yield

 

 —

 

Schedule of change in fair value of the warrant liabilities

 

 

 

 

Fair value as of September 30, 2019

    

$

496,343

Change in fair value

 

 

694,134

Fair value as of December 31, 2019

 

 

1,190,477

Change in fair value

 

 

(69,944)

Fair value as of March 31, 2020

 

$

1,120,533

Change in fair value

 

 

285,284

Fair value as of June 30, 2020

 

$

1,405,817

 

 

 

 

Fair value as of September 30, 2018

 

$

 —

Warrants issued in connection with license acquired

 

 

104,902

Fair value as of December 31, 2018

 

 

104,902

Change in fair value

 

 

38,702

Fair value as of March 31, 2019

 

$

143,604

Change in fair value

 

 

13,240

Fair value as of June 30, 2019

 

$

156,844

 

Schedule of anti dilutive securities excluded from the computation of diluted weighted average shares

 

 

 

 

 

 

 

As of June 30,

 

    

2020

    

2019

Common stock purchase options

 

6,514,466

 

3,337,406

Unvested restricted stock

 

1,250

 

1,307,001

Common stock purchase warrants

 

715,939

 

101,847

Convertible notes

 

 —

 

613,276

 

 

7,231,655

 

5,359,530